<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298922</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 0003</org_study_id>
    <secondary_id>TULLIS04A0</secondary_id>
    <nct_id>NCT00298922</nct_id>
  </id_info>
  <brief_title>Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex</brief_title>
  <official_title>Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary infection with Burkholderia cepacia complex (BCC) in patients with CF is often
      associated with a more rapid decline in lung function. Because of the resistance of BCC to
      many antibiotics, treatment options are often limited. New therapies to improve outcomes for
      patients infected with BCC are needed.

      However, because of the unpredictable nature of this pulmonary infection in CF, patients with
      BCC infection have been excluded from many CF therapeutic trials.

      Recent published trials in the United States, Australia, and the United Kingdom have all
      demonstrated clinical benefits from prolonged administration of azithromycin in CF. In these
      trials, the vast majority of patients were chronically infected with Pseudomonas aeruginosa.

      Patients with BCC were excluded from the US and UK trials, and only four patients with BCC
      infection were enrolled in the Australian trial. Thus, the effectiveness of azithromycin in
      CF patients infected with BCC is largely unknown and deserves further study.

      The two main ways by which azithromycin is thought to help with the chronic lung infections
      seen in CF are by [a] reducing inflammation and [b] direct effects on the bacteria, in
      particular P. aeruginosa. BCC pulmonary infection in CF is often associated with a large
      inflammatory response similar to or more severe than P. aeruginosa infection. If azithromycin
      works mainly by an anti-inflammatory mechanism, it should also be helpful in CF patients
      infected with BCC.

      Alternatively, azithromycin could have a direct effect on BCC as seen with P. aeruginosa as
      the two bacteria have many similarities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN

        -  Overview

        -  This is a single center, randomized, double-blinded, placebo-controlled 24 week trial of
           azithromycin in adults with CF chronically infected with BCC. The investigational
           therapy will be added to usual therapy in patients who are clinically stable at the time
           of enrollment. After 168 days, the study drug will be discontinued and participants will
           be evaluated at 196 days off of study drug for 28 days. At that visit, participants will
           be invited to continue in an open label observational study of azithromycin for 168
           additional days. Thus, the duration of the study will be 52 weeks (364 days).

        -  Day 0- Day 168 on Study Drug (24 weeks)

        -  Day 169- Day 196 off Study Drug (4 weeks)

        -  Day 197 - Day 364 on OPEN label Azithromycin (24 weeks)

        -  Measuring primary and secondary endpoints

        -  Primary efficacy endpoint

        -  Primary efficacy endpoint will be the quantitative changes in lung function as measured
           by FEV1 in % predicted from baseline to completion of the 24 week treatment period.
           (refer to Appendix C for ATS guidelines).

        -  Primary safety endpoints

        -  Primary safety endpoints collected over the 24 week treatment period will be:

             -  Adverse events such as gastrointestinal complaints, ototoxicity, tinnitus,
                hepatitis or leukopenia as determined by:

                (i) open ended questioning of study subjects at study visits (ii) laboratory tests
                for elevated liver function tests or hematologic abnormalities,

             -  Changes in lung microbiology as determined by:[86] (i) Emergent B. cenocepacia
                (genomovar III) (ii) Emergent non-B. cenocepacia genomovars (iii) Emergent NTM[87]
                (iv) Emergent azithromycin resistant NTM (v) Emergent Aspergillus species (vi)
                Emergent MDRO - (S. maltophilia, A. xylosoxidans, or methicillin-resistant S.
                aureus) (vii) Emergent P. aeruginosa (viii) Emergent azithromycin resistant S.
                aureus

        -  Secondary efficacy endpoints

        -  Secondary efficacy endpoints will be:

        -  Quantitative changes in lung function as measured by change in relative percent change
           in FEV1 and FVC from baseline to completion of the 24 week treatment period.

        -  Quantitative change in FEV1 and FVC in liters in CF study subjects treated with
           azithromycin compared with those CF study subjects treated with placebo. FEV1 and FVC in
           liters will be measured according to ATS criteria

        -  The number of days until first administration of intravenous antibiotics and/or the use
           of oral tetracycline derivatives minocycline / doxycycline for seven or more days during
           the 24 week period.

        -  The number of pulmonary exacerbations as defined by need for treatment with intravenous
           or oral tetracycline derivative antibiotics for an increase in pulmonary symptoms during
           the 24 week period.

        -  The proportion of patients requiring intravenous antibiotics during the 24 week period.

        -  The number of days of treatment with intravenous antibiotics given during the 24 week
           period.

        -  The proportion of patients hospitalized.

        -  The number of hospital days as calculated by calendar days during the 24 week period.

        -  The proportion of patients requiring oral antibiotics during the 24 week period.

        -  The number of days of treatment with oral non-tetracycline derivative antibiotics given
           during the 24 week period.

        -  Changes in body weight from baseline to completion of the 24 week treatment period.

        -  Change in level of inflammation as measured by the change in serum CRP and ESR from
           baseline to the end of the 24 week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 in % predicted in CF study subjects treated with azithromycin compared with those CF study subjects treated with placebo.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants taking 500 mg tablets orally thrice weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants taking 500 mg tablets orally thrice weekly for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg tablets orally thrice weekly for 24 weeks</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet orally thrice weekly for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent and verbal assent as appropriate has been provided by the subject

          -  Ability to comply with medication use, study visits and study procedures as judged by
             the site Investigator

          -  Diagnosis of CF as defined by two or more clinical features of CF and a documented
             sweat chloride &gt; 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype
             showing two well characterized disease causing mutations

          -  &gt; 18 years of age

          -  Body weight &gt; 40 kg

          -  BCC present in a sputum/throat culture &gt; 1 year prior to screening and at screening

          -  FEV1 % predicted &gt; 30% as calculated by the Knudsen reference equations

          -  Room air oximetry &gt; 88% at rest

          -  Post-menarche females must be surgically sterile or using an effective form of
             contraception

          -  Predicted to live &gt; 1 year and clinically stable at that time of enrollment as judged
             by the investigator.

        Exclusion Criteria:

          -  History of chronic macrolide use, defined as regular macrolide antibiotic use within a
             three month period prior to enrollment in the study.

          -  AST or ALT &gt; 2.5 times the upper limit of normal performed at the local laboratories
             on two occasions prior to randomization.

          -  Investigational drug use within 30 days of screening

          -  History of alcohol, illicit drug or medication abuse within 1 year of screening

          -  Use of intravenous antibiotics or oral antibiotics within 14 days of screening.

          -  Use of low dose oral antibiotics (e.g. macrolides, tetracycline, sulfa) for acne or
             other conditions within 30 days of screening

          -  Use of systemic corticosteroids (&gt; 20 mg of prednisone per day) within 30 days of
             screening

          -  Initiation of TOBIÂ®, high dose ibuprofen, or rhDNase within 60 days of screening

          -  History of lung transplantation or currently on lung transplant list

          -  History of allergy to a macrolide antibiotic

          -  AFB smear positive at screening suggesting current NTM infection.

          -  Positive serum pregnancy test at screening (to be performed on all post-menarche
             females)

          -  Absolute neutrophil count &lt; 1000 performed at the local laboratories on two occasions
             prior to randomization

          -  Creatinine &gt; 1.5 times normal performed at the local laboratories on two occasions
             prior to randomization.

          -  Chest x-ray changes or physical findings at screening that would compromise the safety
             of the patient or the quality of the study data

          -  Other major organ dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Tullis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>July 30, 2009</last_update_submitted>
  <last_update_submitted_qc>July 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Elizabeth Tullis</name_title>
    <organization>St. Michael's Hospital</organization>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Burkholderia cepacia complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

